Outcomes of First-Line Pembrolizumab Monotherapy for PD-L1–positive (TPS ≥50%) Metastatic NSCLC at US Oncology Practices

In this Publication Perspective, lead author Vamsidhar Velcheti, New York University, provides a summary of article 'Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices' published in Immunotherapy that looks at real-world outcomes with first-line pembrolizumab monotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor expression ≥50%.